Markets:

Overview

News

Currencies

International

Treasuries

Regeneron Pharmaceuticals (NQ:REGN)

788.12 -15.05 (-1.87%)

Streaming Delayed Price Updated: 1:33 PM EST, Feb 17, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Regeneron Pharmaceuticals

< Previous 1 2

...

22 23 24 25 26 27 28 29 30

...

59 60 Next >

5 Healthcare Stocks to Buy for 2024 ↗

April 02, 2024

Healthcare stocks have been some of the top performers in 2024, and thanks to the potential of AI, these names will just keep heating up.

Via InvestorPlace

Topics Artificial Intelligence

Regeneron to Report First Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on May 2, 2024

April 01, 2024

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Here's How Much $100 Invested In Regeneron Pharmaceuticals 10 Years Ago Would Be Worth Today ↗

April 01, 2024

Via Benzinga

Behind the Scenes of Regeneron Pharmaceuticals's Latest Options Trends ↗

March 28, 2024

Via Benzinga

Race To Treat Alzheimer's Disease Is Heating Up Despite Eli Lilly's Setback ↗

March 28, 2024

The FDA has delayed making a decision on Eli Lilly's donanemab, pending an advisory committee meeting.

Via Investor's Business Daily

Decoding 12 Analyst Evaluations For Regeneron Pharmaceuticals ↗

March 26, 2024

Via Benzinga

Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) is a Leading Gainer in Friday Morning Trading

March 22, 2024

Via Investor Brand Network

Stock-Split Watch: Are These 2 Top Growth Stocks Next? ↗

March 28, 2024

Shares of Eli Lilly and Regeneron are both well into the range where splits would make sense.

Via The Motley Fool

3 Biotech Stocks to Buy for the Next Bull Run: March 2024 ↗

March 26, 2024

These biotech stocks to buy are well positioned for growth, and will generate solid returns for investors in the next bull run.

Via InvestorPlace

FDA Delays Decision For Regeneron's Inaugural Blood Cancer Therapy, Highlights Trial Concerns ↗

March 25, 2024

The FDA issues complete response letters to Regeneron Pharmaceuticals Inc's BLA for odronextamab in relapsed/refractory follicular lymphoma and diffuse large B-cell lymphoma, requesting more trial data...

Via Benzinga

Regeneron Provides Update on Biologics License Application for Odronextamab

March 25, 2024

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Regeneron Pharmaceuticals Unusual Options Activity For March 20 ↗

March 20, 2024

Via Benzinga

Unpacking the Latest Options Trading Trends in Regeneron Pharmaceuticals ↗

March 15, 2024

Via Benzinga

Decoding Regeneron Pharmaceuticals's Options Activity: What's the Big Picture? ↗

March 01, 2024

Via Benzinga

The Analyst Verdict: Regeneron Pharmaceuticals In The Eyes Of 10 Experts ↗

February 27, 2024

Via Benzinga

Hot Stocks: The 3 Best Opportunities for Investing in Weight Loss Drugs ↗

March 22, 2024

The market for weight loss drug stocks is massive, and these three companies could be the biggest beneficiaries of this trend.

Via InvestorPlace

The 3 Most Undervalued Biotech Stocks to Buy in March 2024 ↗

March 13, 2024

These 3 undervalued biotech stocks have been left behind so far but things could begin to turn around as we head into March.

Via InvestorPlace

NVIDIA To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Wednesday ↗

March 13, 2024

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Via Benzinga

High School Seniors Win $1.8 Million at Regeneron Science Talent Search 2024 for Innovative Scientific Research on Artificial Intelligence, Cancer Metabolism and Mathematical Optimization

March 12, 2024

$250,000 top award goes to Achyuta Rajaram in the nation’s oldest and most prestigious Science, Technology, Engineering and Math (STEM) competition for high school seniors

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

(REGN) - Analyzing Regeneron Pharmaceuticals's Short Interest ↗

February 22, 2024

Via Benzinga

Praluent® (alirocumab) Injection Receives FDA Approval to Treat Children with Genetic Form of High Cholesterol

March 11, 2024

Approval extends treatment of Praluent to children aged 8 and older with heterozygous familial hypercholesterolemia (HeFH)

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Missed Out on Eli Lilly? 3 Healthcare Stocks With Big Catalysts on the Horizon. ↗

March 09, 2024

Good news could be in store for all three of these drugmakers.

Via The Motley Fool

Here's How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 20 Years ↗

March 08, 2024

Via Benzinga

2 Biotech Stocks to Buy Hand Over Fist in March ↗

March 08, 2024

These stocks are worth buying in most months of the year.

Via The Motley Fool

EYLEA® HD (aflibercept) Injection 8 mg Pivotal Data in Wet Age-related Macular Degeneration (wAMD) and Diabetic Macular Edema (DME) Published in The Lancet

March 08, 2024

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Biotechs on the Rise: 3 Stocks to Buy for a Shot of Profits ↗

March 04, 2024

Given recent industry performance, the enthusiasm investors have for biotech stocks to buy is low. But these three companies seem promising.

Via InvestorPlace

Median Drug Prices For Rare Diseases Hit $300K In 2023, Report Highlights Lack of Clear Rationale Behind Escalating Drug Prices ↗

February 26, 2024

Latest pharmaceutical trends in the U.S. as drug prices surged 35% in 2023. Uncover insights into the industry's focus on rare diseases, escalating costs, and the impact on FDA-approved drugs.

Via Benzinga

Here's How Much $100 Invested In Regeneron Pharmaceuticals 20 Years Ago Would Be Worth Today ↗

February 26, 2024

Via Benzinga

Weight-Loss Drugs Have One Big Problem. These Drugmakers Are Taking It On. ↗

February 23, 2024

Weight-loss drugs from Novo Nordisk and Eli Lilly lead to massive weight loss. But not all of that weight loss is healthy.

Via Investor's Business Daily

Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of COPD with Type 2 Inflammation

February 23, 2024

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

< Previous 1 2

...

22 23 24 25 26 27 28 29 30

...

59 60 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.